John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

New standards and personalised approaches in cholangiocarcinoma Volume 26, supplement 6, Décembre 2019

  • [1] Valle JW, Borbath I, Khan SA, et al. Biliary cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016 ; 27 : v28-v37.
  • [2] Bridgewater J., Galle P.R., Khan S.A. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289.
  • [3] Forner A., Vidili G., Rengo M. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39:98-107. Suppl. 1
  • [4] Vilana R., Forner A., Bianchi L. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology. 2010;51:2020-2029.
  • [5] Hainsworth J.D., Rubin M.S., Spigel D.R. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site : a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31:217-223.
  • [6] Mavros M.N., Economopoulos K.P., Alexiou V.G., Pawlik T.M. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma : Systematic Review and Meta-analysis. JAMA Surg. 2014;149:565-574.
  • [7] Darwish Murad S., Kim W.R., Harnois D.M. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88-98.
  • [8] Horgan A.M., Amir E., Walter T., Knox J.J. Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934-1940.
  • [9] Takada T., Amano H., Yasuda H. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685-1695.
  • [10] Edeline J., Bonnetain F., Phelip J.M. Gemox versus surveillance following surgery of localized biliary tract cancer : Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol. 2019;37:658-667.
  • [11] Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer : The BILCAP randomized study. Lancet Oncol 2019 ; 20 : 663-673.
  • [12] Wiggers J.K., Ruys A.T., Groot Koerkamp. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29:1582-1594.
  • [13] Boehm L.M., Jayakrishnan T.T., Miura J.T. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111:213-220.
  • [14] Al-Adra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis. Eur J Surg Oncol 2015 ; 41 : 120-127.
  • [15] Edeline J, Touchefeu T, Guiu B, et al. JAMA Oncol 2019, in press.
  • [16] Hong T.S., Wo J.Y., Yeap B.Y. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34:460-468.
  • [17] Tao R., Krishnan S., Bhosale P.R. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016;34:219-226.
  • [18] Deviere J., Baize M., de Toeuf J., Cremer M. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc. 1988;34:95-101.
  • [19] Vienne A., Hobeika E., Gouya H. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc. 2010;72:728-735.
  • [20] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-1281.
  • [21] Lamarca A, Palmer DH, Wasan HS, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC + mFOLFOX) for patients with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. ASCO meeting 2019 2019, Abstract #4003.
  • [22] Valle J.W., Lamarca A., Goyal L. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017;7:943-962. 9
  • [23] Neuzillet C., Rousseau B., Kocher H. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1 : GI carcinomas. Pharmacol Ther. 2017;174:145-172.
  • [24] Jain A., Kwong L.N., Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol. 2016;17:58.
  • [25] Churi C.R., Shroff R., Wang Y. Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS One. 2014;9:e115383.
  • [26] Wang P., Dong Q., Zhang C. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091-3100.
  • [27] Goyal L., Govindan A., Sheth R.A. Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist. 2015;20:1019-1027.
  • [28] Wu Y.M., Su F., Kalyana-Sundaram S. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636-647.
  • [29] Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers : An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer 2017 ; 87 : 122-130.
  • [30] Valle J.W., Lamarca A., Goyal L. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7:943-962.
  • [31] Lowery M.A., Burris HA 3rd, Janku F. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study. Lancet Gastroenterol Hepatol. 2019;4:711-720.
  • [32] Abou-Alfa GK, Macarulla Mercade T, Javle M et al. ClarIDHy : A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. ESMO meeting 2019 2019, Abstract LBA10.
  • [33] Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: A unique clinical phenotype. JCO Precision Oncology 2018 ; 1-12.
  • [34] Vogel A, Sahai V, Hollebecque A, et al. FIGHT-202: a phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). ESMO meeting 2019, Abstract LBA 40.
  • [35] Hollebecque A, Silverman I, Owens S, et al. Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial ESMO meeting 2019, Abstract 720P.
  • [36] Ross J.S., Wang K., Gay L. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19:235-242.
  • [37] Drilon A., Nagasubramanian R., Blake J.F. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017;7:963-972.
  • [38] Drilon A., Laetsch T.W., Kummar S. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731-739.
  • [39] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017 ; 357 : 409-413.
  • [40] Bang YJ, Ueno M, Malka D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma : Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. ASCO meeting 2019, Abstract 4079.
  • [41] Kim R, Kim D, Alese O, et al. A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). ESMO GI meeting 2018, Abstract 0009.